Survival Effects of Radiotherapy on Patients Newly Diagnosed with Distant Metastatic Nasopharyngeal Carcinoma in Non-High-Incidence Areas

References

• Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-031178151
   PubMed Web of Science ®Google Scholar
• Wei KR, Zheng RS, Zhang SW, Liang ZH, Li ZM, Chen WQ. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer. 2017;36(1):90. doi:10.1186/s40880-017-0257-929122009
   PubMedGoogle Scholar
• Huifang CQ, Yin L, Shuzheng L, et al.Analysis of incidence and mortality of nasopharyngeal carcinoma in Henan Province, 2016. Chin J Oncol Prev Treat. 2021;13(3):262–266.
   Google Scholar
• Wang F, Jiang C, Wang L, et al. Different risk target volumes for nasopharyngeal carcinoma treated with simultaneous integrated boost intensity-modulated radiotherapy. J Cancer. 2020;11(17):5210–5222. doi:10.7150/jca.4576732742467
   PubMed Web of Science ®Google Scholar
• Rusthoven CG, Lanning RM, Jones BL, et al. Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol. 2017;124(1):139–146. doi:10.1016/j.radonc.2017.03.01928433411
   PubMed Web of Science ®Google Scholar
• Zhang CH, Pan YB, Zhang QW, et al. The influence of local therapy on the survival of patients with metastatic rectal cancer: a population-based, propensity-matched study. J Cancer Res Clin Oncol. 2017;143(9):1891–1903. doi:10.1007/s00432-017-2442-228534172
   PubMed Web of Science ®Google Scholar
• Wang CJ, Christie A, Lin MH, et al. Safety and efficacy of stereotactic ablative radiation therapy for renal cell carcinoma extracranial metastases. Int J Radiat Oncol Biol Phys. 2017;98(1):91–100. doi:10.1016/j.ijrobp.2017.01.03228587057
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England: 1990). 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• National Cancer Institute (US). Common terminology criteria for adverse events (CTCAE) v4.0. 2009.
   Google Scholar
• You R, Liu YP, Huang PY, et al. Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol. 2020;6(9):1345–1352. doi:10.1001/jamaoncol.2020.180832701129
   PubMed Web of Science ®Google Scholar
• Yu MC, Garabrant DH, Huang TB, Henderson BE. Occupational and other non-dietary risk factors for nasopharyngeal carcinoma in Guangzhou, China. Int J Cancer. 1990;45(6):1033–1039. doi:10.1002/ijc.29104506092351484
   PubMed Web of Science ®Google Scholar
• Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, Yu MC. Non-dietary risk factors for nasopharyngeal carcinoma in Shanghai, China. Int J Cancer. 2000;85(3):364–369. doi:10.1002/(SICI)1097-0215(20000201)85:3<364::AID-IJC12>3.0.CO;2-C10652428
   PubMed Web of Science ®Google Scholar
• Golden EB, Chhabra A, Chachoua A, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 2015;16(7):795–803. doi:10.1016/S1470-2045(15)00054-626095785
   PubMed Web of Science ®Google Scholar
• Lang J, Gao L, Guo Y, et al. Comprehensive treatment of squamous cell cancer of head and neck: Chinese expert consensus 2013. Future Oncol (London, England). 2014;10(9):1635–1648. doi:10.2217/fon.14.44
   PubMed Web of Science ®Google Scholar
• Lang J, Hu C, Lu T, Pan J, Lin T. Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives. Cancer Manag Res. 2019;11:6365–6376. doi:10.2147/CMAR.S19754431372041
   PubMed Web of Science ®Google Scholar
• Sun X-S, Liu L-T, Liu S-L, et al. Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein-Barr virus DNA level and tumor response to palliative chemotherapy. BMC Cancer. 2019;19(1):92. doi:10.1186/s12885-019-5281-530665378
   PubMed Web of Science ®Google Scholar
• Bhattacharyya T, Babu G, Kainickal CT. Current role of chemotherapy in nonmetastatic nasopharyngeal cancer. J Oncol. 2018;2018:3725837. doi:10.1155/2018/372583730364069
   PubMed Web of Science ®Google Scholar
• Li WZ, Hua X, Lv SH, et al. A scoring system based on nutritional and inflammatory parameters to predict the efficacy of first-line chemotherapy and survival outcomes for de novo metastatic nasopharyngeal carcinoma. J Inflamm Res. 2021;14:817–828. doi:10.2147/JIR.S29671033732007
   PubMed Web of Science ®Google Scholar
• Zou X, You R, Liu H, et al. Establishment and validation of M1 stage subdivisions for de novo metastatic nasopharyngeal carcinoma to better predict prognosis and guide treatment. Eur J Cancer (Oxford, England: 1990). 2017;77:117–126. doi:10.1016/j.ejca.2017.02.029
   PubMed Web of Science ®Google Scholar
• Li WZ, Lv SH, Liu GY, et al. Development of a prognostic model to identify the suitable definitive radiation therapy candidates in de novo metastatic nasopharyngeal carcinoma: a real-world study. Int J Radiat Oncol Biol Phys. 2021;109(1):120–130. doi:10.1016/j.ijrobp.2020.08.04532853711
   PubMed Web of Science ®Google Scholar
• Shen LJ, Wang SY, Xie GF, et al. Subdivision of M category for nasopharyngeal carcinoma with synchronous metastasis: time to expand the M categorization system. Chin J Cancer. 2015;34(10):450–458. doi:10.1186/s40880-015-0031-926264052
   PubMedGoogle Scholar
• Wang WY, Twu CW, Chen HH, et al. Long-term survival analysis of nasopharyngeal carcinoma by plasma Epstein-Barr virus DNA levels. Cancer. 2013;119(5):963–970. doi:10.1002/cncr.2785323065693
   PubMed Web of Science ®Google Scholar
• Wang W-Y, Twu C-W, Chen -H-H, et al. Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma. Clin Cancer Res. 2010;16(3):1016–1024. doi:10.1158/1078-0432.CCR-09-279620103659
   PubMed Web of Science ®Google Scholar
• An X, Wang FH, Ding PR, et al. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer. 2011;117(16):3750–3757. doi:10.1002/cncr.2593221319149
   PubMed Web of Science ®Google Scholar
• Sun XS, Liang YJ, Liu SL, et al. Establishment and validation of a nomogram for predicting survival in patients with de novo metastatic nasopharyngeal carcinoma. Oral Oncol. 2019;94:73–79. doi:10.1016/j.oraloncology.2019.05.01531178215
   PubMed Web of Science ®Google Scholar
• Tang XR, Li YQ, Liang SB, et al. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol. 2018;19(3):382–393. doi:10.1016/S1470-2045(18)30080-929428165
   PubMed Web of Science ®Google Scholar
• Han C, Yang JL, Yao KT. [Gene expression profiling of nasopharyngeal carcinoma cell line 5-8F-EGFP and the liver metastatic 5-8F-H3B-EGFP cells]. Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University. 2011;31(3):473–477. Chinese.21421486
   PubMedGoogle Scholar
• Zhou GQ, Tang LL, Mao YP, et al. Baseline serum lactate dehydrogenase levels for patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma: a predictor of poor prognosis and subsequent liver metastasis. Int J Radiat Oncol Biol Phys. 2012;82(3):e359–e365. doi:10.1016/j.ijrobp.2011.06.196722000748
   PubMed Web of Science ®Google Scholar
• Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet (London, England). 2016;387(10022):1012–1024. doi:10.1016/S0140-6736(15)00055-0
   PubMed Web of Science ®Google Scholar
• Yang Y, Qu S, Li J, et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22:1162–1174. doi:10.1016/S1470-2045(21)00302-834174189
   PubMed Web of Science ®Google Scholar
• Sun X-S, Liu S-L, Liang Y-J, et al. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: a propensity score matching study. Cancer Commun (Lond). 2020;40(1):32–42. doi:10.1002/cac2.1200432112522
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–2058. doi:10.1016/S0140-6736(18)32487-530982687
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020;38(25):2830–2838. doi:10.1200/JCO.20.0081832484754
   PubMed Web of Science ®Google Scholar
• McDowell L, Rischin D, Lee AWM. Locoregional radiation therapy for de novo metastatic nasopharyngeal cancer: one size fits all? Int J Radiat Oncol Biol Phys. 2021;109(1):131–133. doi:10.1016/j.ijrobp.2020.10.00133308694
   PubMed Web of Science ®Google Scholar